The addition of CDK4/6 inhibitors to endocrine therapy has significantly improved both PFS and OS in this patient population, establishing this combination as the standard of care for advanced HR+ HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.